Clozapine Combined with Sulfamethoxazole Enhances the Therapeutic Effect on Refractory Schizophrenia Patients
Objective:Study and explore the efficacy of clozapine combined with sulfamethoxazole in enhancing the treatment of refractory schizophrenia patients.Method:110 cases of refractory schizophrenia patients admitted to Fuzhou Neuropsychiatric Hospital from January 2021 to December 2023 were selected as the study objects,and were divided into observation group and control group by random number table method,with 55 cases in each group.The control group was treated with clozapine tablets orally,while the observation group was treated with clozapine combined with amisulpride.All patients were treated for 3 courses.The clinical efficacy,symptom score,sex hormone level,quality of life score and treatment safety were compared between the two groups.Result:The total effective rate of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).After treatment,all scores of Postive and Negative Syndrome Scale(PANSS)in the observation group were lower than those in the control group(P<0.05).After treatment,the levels of estradiol(E2),prolactin(PRL),progesterone(P),and testosterone(T)were lower in the observation group than those in the control group,and the difference was statistically significant(P<0.05).After treatment,all scores of the Quality of Life Scale(QLS)in the observation group were lower than those in the control group,and the difference was statistically significant(P<0.05).There was no difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Clozapine combined with amisulpride enhancement therapy is effective in the treatment of refractory schizophrenia patients,which can effectively control the symptoms of schizophrenia,reduce the impact on the level of sex hormones of the patients,improve the quality of life of the patients,and have good therapeutic safety.
Refractory schizophreniaClozapineAmisulprideSex hormoneClinical efficacyQuality of life